<DOC>
	<DOC>NCT00527137</DOC>
	<brief_summary>Open-label, randomized study of NESP in pediatric subjects 18 years of age or younger. Subjects will receive study drug (NESP or rHuEPO) for 28 weeks after a 2 week screening and baseline period. During the study, procedures include bloodwork for laboratory assessments and vital signs. Dose titration determined by hemoglobin values taken weekly during the study. Antibody samples taken at baseline and during the end of study assessments. A physical examination and laboratory tests will conclude the study.</brief_summary>
	<brief_title>NESP Pediatric Study</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>1 to 18 years of age ESRD receiving dialysis or CRI with eGFR less than 30 mL/min Baseline hemoglobin 9.5 12.5 g/dL and iron replete Stable rHuEPO therapy for 8 weeks Scheduled for a livingrelated kidney transplant Uncontrolled blood pressure seizure activity Hyperparathyroidism Major surgery within 12 weeks or active inflammatory disease Currently receiving antibiotics Clinical evidence of malignancy Pregnant or breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>